Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.37 |
| ▸ | BCHE | P06276 | 7/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417417 | 0.81 | ACHE (0.48) | ACHEBCHESLC6A2SLC6A4TDP1 | |
| SCHEMBL415634 | 0.78 | MC4R (0.42) | ACHEBCHECHRM2CHRM1 | |
| SCHEMBL414460 | 0.78 | ACHE (0.51) | ACHEBCHECHRM2CHRM1TDP1 | |
| SCHEMBL417570 | 0.77 | ACHE (0.50) | ACHEBCHECHRM2CHRM1SLC6A2 | |
| SCHEMBL415188 | 0.77 | ACHE (0.54) | ACHEBCHECHRM2CHRM1SLC6A2 | |
| SCHEMBL416389 | 0.76 | ACHE (0.50) | ACHEBCHESLC6A2SLC6A4TDP1 | |
| SCHEMBL417559 | 0.75 | ACHE (0.52) | ACHEBCHECHRM2CHRM1TDP1 | |
| SCHEMBL412451 | 0.75 | ACHE (0.54) | ACHEBCHECHRM2CHRM1TDP1 | |
| SCHEMBL413023 | 0.74 | ACHE (0.52) | ACHEBCHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL413455 | 0.73 | ACHE (0.54) | ACHEBCHECHRM2CHRM1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | ACHE 4296/4885BCHE 3039/4885CHRM2 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.